Chanca Piedra for Kidney Stones

Calcium oxalate kidney stone crystal microscopy with shape modification Chanca piedra anti-crystallization mechanism in renal tubule Five-stage kidney stone formation cascade with chanca piedra intervention points Post-shock-wave-lithotripsy stone fragments passing through ureter

Chanca Piedra's English name is a literal translation of the Spanish — "stone breaker." Centuries of Amazonian and Andean folk use anticipated what modern pharmacology has refined: the herb does not literally dissolve mature stones, but it does measurably reduce crystal formation, change crystal shape so fragments pass more easily, and assist clearance after shock-wave lithotripsy (SWL). This page covers the patient-facing protocol — the evidence, the dosing, when it works, and where it doesn't.

Table of Contents

  1. The "Stone Breaker" Name
  2. What Chanca Piedra Actually Does
  3. Calcium Oxalate Stones (~80% of cases)
  4. Uric Acid Stones
  5. Cystine and Struvite Stones
  6. The Nishiura 2004 Trial
  7. Micali 2006: Post-SWL Fragment Passage
  8. Urinary Chemistry Effects
  9. Dosing Protocols
  10. Chanca Piedra vs Standard Prevention
  11. Evidence Quality
  12. Key Research Papers
  13. Connections

The "Stone Breaker" Name

Two languages, same translation. Quebra pedra in Portuguese (Brazilian Amazon) and chanca piedra in Spanish (Andean and Peruvian) both literally mean "stone breaker." The name is centuries old in indigenous Amazonian and Andean traditional medicine, where Phyllanthus niruri was prepared as a tea or decoction for "kidney pain" and the passage of stones in the urine. Modern pharmacological investigation began in the 1980s and 1990s at the Federal University of São Paulo (UNIFESP) under Nicolaos Barros and Ita Pfeferman Heilberg, who built the experimental framework that explained how a folk remedy actually worked.

Back to Table of Contents

What Chanca Piedra Actually Does

The traditional name oversells the mechanism. Chanca Piedra is not literally a stone-dissolving solvent. The substantiated effects are subtler and arguably more useful as a long-term strategy:

The Barros 2003 rat experiments at UNIFESP established the anti-adherence mechanism by showing that Chanca Piedra-treated tubular cells had significantly less calcium oxalate crystal binding. That single mechanism explains most of the downstream clinical observations.

Back to Table of Contents

Calcium Oxalate Stones (~80% of cases)

Calcium oxalate stones are by far the most common — about 80% of all kidney stones in the US. They form when urine becomes supersaturated with calcium and oxalate, when crystals nucleate in the renal collecting system, when those crystals stick to the tubular epithelium, and when more crystals layer onto the seed.

Chanca Piedra interrupts this cascade at multiple points. The Nishiura 2004 trial measured urinary chemistry changes in 56 idiopathic calcium oxalate stone formers given 450 mg of dried Phyllanthus niruri extract three times daily for three months. The hypercalciuric subgroup (those whose urine carried excess calcium) showed significant reduction in urinary calcium — the principal driver of new stone formation. The overall stone-promoting profile of the urine improved without any reported adverse effects.

For a calcium oxalate stone-former, the practical implication is that Chanca Piedra is a reasonable adjunct to mainstream prevention (high fluid intake, dietary moderation of oxalate-rich foods like spinach and almonds, dietary calcium kept normal rather than restricted, salt and animal-protein moderation) for slowing or preventing new stone growth. It is not a replacement for these foundations.

Back to Table of Contents

Uric Acid Stones

Uric acid stones account for about 10% of all kidney stones and are particularly common in patients with gout, metabolic syndrome, persistent low urine pH, or chronic diarrhea (which can produce acidic urine through bicarbonate loss). Uric acid is much more soluble at urinary pH above 6.5; below pH 5.5 it crystallizes.

Animal data and small human studies suggest Chanca Piedra has modest uricosuric (urate-excreting) and alkalinizing effects, lowering serum uric acid while raising urinary pH toward the soluble range. The mechanism is less well-characterized than the calcium oxalate effects, but is consistent with the xanthine oxidase inhibition documented in pharmacology studies (see Uric Acid & Gout).

For uric acid stone formers, Chanca Piedra is a reasonable adjunct to potassium citrate or sodium bicarbonate, which remain the primary alkalinizing therapies, and to allopurinol or febuxostat, which directly lower serum urate.

Back to Table of Contents

Cystine and Struvite Stones

The honest answer for these less-common stone types: there is essentially no high-quality human data supporting Chanca Piedra. A few in-vitro studies suggest reduced struvite crystal nucleation in urinary-tract-infection models (struvite stones form in alkaline urine in the presence of urease-producing bacteria like Proteus). Cystinuria response to Chanca Piedra is anecdotal and absent from any randomized trial literature.

If you have cystine or struvite stones, the standard treatments — tiopronin or D-penicillamine for cystine, plus aggressive hydration and pH control; antibiotics plus surgical clearance for struvite — are not optional. Chanca Piedra at most plays an adjunctive role and should not delay definitive management.

Back to Table of Contents

The Nishiura 2004 Trial

The single most-cited human study. Nishiura et al. (UNIFESP, São Paulo), published in Urological Research:

Nishiura is the cleanest human study of Chanca Piedra for stone prevention. Its limits: open-label, no placebo arm, single center, modest sample size, three-month duration only. The mechanism it confirms (hypercalciuria reduction) is biologically plausible and consistent with the rat-model data from Barros.

Back to Table of Contents

Micali 2006: Post-SWL Fragment Passage

The strongest evidence for Chanca Piedra in actual stone-passage clinical practice. Micali et al. (Italy), published in The Journal of Urology:

This is the use case with the strongest evidence: after a urologist has fragmented your stones with shock waves, Chanca Piedra at 2 g/day for three months helps the fragments make their way out. The 24-percentage-point improvement in stone-free rate is clinically meaningful.

The Pucci 2018 review/meta-analysis (International Brazilian Journal of Urology) confirmed the post-SWL adjuvant signal across multiple smaller trials, while flagging the heterogeneity and small sample sizes that limit strong conclusions.

Back to Table of Contents

Urinary Chemistry Effects

From the Nishiura trial and supporting studies, the documented urinary chemistry effects:

None of these are dramatic. Chanca Piedra is a tilt-the-scales intervention, not a transformation. For perspective: a thiazide diuretic typically reduces 24-hour urinary calcium by 25–50%; Chanca Piedra's effect in the hypercalciuric subgroup of Nishiura was in the 10–20% range.

Back to Table of Contents

Dosing Protocols

Three patient-facing protocols supported by the trial data:

Post-SWL fragment-passage adjuvant

Hypercalciuria prevention

General "stone history" maintenance

For details on standardization, extract types, and quality criteria, see Forms, Dosing & Standardization.

Back to Table of Contents

Chanca Piedra vs Standard Prevention

Standard medical stone prevention has decades of Level-1 randomized-trial evidence:

Chanca Piedra fits as a complement to these, not a replacement. Reasonable scenarios:

It is not a reasonable substitute for evidence-based therapy in patients with significant stone disease, recurrent stones, or genetic stone-formation syndromes (cystinuria, primary hyperoxaluria).

Back to Table of Contents

Evidence Quality

Well-supported:

Plausible but preliminary:

Unsupported by evidence:

Back to Table of Contents

Key Research Papers

  1. Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N. Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urological Research, 2004 Oct;32(5):362-6. — PubMed
  2. Micali S, Sighinolfi MC, Celia A, et al. Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. The Journal of Urology, 2006 Sep;176(3):1020-2. — PubMed
  3. Barros ME, Schor N, Boim MA. Effects of an aqueous extract from Phyllanthus niruri on calcium oxalate crystallization in vitro. Urological Research, 2003 Feb;31(1):26-31. — PubMed
  4. Pucci ND, Marchini GS, Mazzucchi E, et al. Effect of Phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention. International Brazilian Journal of Urology, 2018. — PubMed
  5. Freitas AM et al. The effect of Phyllanthus niruri on urinary inhibitors of calcium oxalate crystallization. BJU International. — PubMed
  6. Campos AH, Schor N. Phyllanthus niruri inhibits calcium oxalate endocytosis by renal tubular cells. Nephron. — PubMed

PubMed Topic Searches

  1. PubMed: Phyllanthus and calcium oxalate
  2. PubMed: Phyllanthus post-SWL adjuvant
  3. PubMed: Stone-prevention RCTs
  4. PubMed: Phyllanthus hypercalciuria
  5. PubMed: Uric acid stones
  6. PubMed: Urinary citrate & pH

Back to Table of Contents

Connections

Back to Table of Contents